Bladder cancer remains a significant challenge in urology, with high recurrence rates and limited effective treatments.
Current therapies, including transurethral resection, chemotherapy and immunotherapy, often fall short due to poor drug retention, systemic toxicity and resistance development.
Photodynamic therapy (PDT) and photothermal therapy (PTT) offer promising alternatives, but their clinical efficacy is often limited by oxygen dependence, poor selectivity, and suboptimal pharmacokinetics.
Now, researchers from the University of California, Davis, USA, led by Professor Tzu-Yin Lin, Professor Yuanpei Li, and Professor Jinhwan Kim, have developed a novel multifunctional nanoparticle platform that integrates phototherapy with real-time imaging capabilities, offering a significant breakthrough in bladder cancer treatment.
Why These Nanoparticles Matter
The newly developed pyropheophorbide a-bisaminoquinoline conjugate lipid nanoparticles (PPBC LNPs) combine powerful photodynamic and photothermal effects, effectively inducing bladder cancer cell death.
PPBC LNPs also inhibit autophagy, a process that can lead to treatment resistance, thereby enhancing the efficacy of phototherapy.
These nanoparticles possess remarkable photoacoustic (PA) and fluorescence (FL) imaging capabilities, enabling high-resolution, deep tissue penetration, and high-sensitivity imaging for tracking drug biodistribution and phototherapy efficacy.
IS TISSUE THE ISSUE?
Innovative Design and Mechanisms
PPBC LNPs were synthesised using a microfluidic platform, ensuring uniform size and scalability. The nanoparticles exhibited excellent biocompatibility, stability, and long-term storage potential, with an average size of 107 nm and a narrow polydispersity index (PDI) of 0.15.
PPBC LNPs demonstrated potent PDT and PTT effects, with significant ROS production and hyperthermia generation under light irradiation. The photothermal conversion efficiency was calculated to be 32.7%, indicating efficient heat generation for cell ablation.
The nanoparticles’ strong optical absorption in the NIR region enabled effective PA imaging, while their fluorescence properties allowed for FL imaging, providing complementary information on drug accumulation and therapeutic response.
In Vivo Efficacy and Safety
In both subcutaneous and orthotopic bladder cancer mouse models, PPBC LNPs significantly inhibited tumour growth. Notably, several tumours were completely ablated after just two doses of the nanoparticles combined with laser treatment.
PA and FL imaging confirmed the efficient accumulation of PPBC LNPs at the tumour site, with prolonged retention observed for up to 6 days. This dual imaging approach optimised phototherapy timing and facilitated real-time biodistribution tracking.
The treatment showed good safety profiles, with stable body weights and no significant toxicity observed in major organs.
Future Outlook
The scalable production and multifunctional design of PPBC LNPs highlight their potential for clinical development. Further studies in larger animal models are underway to evaluate their efficacy and safety in more clinically relevant settings.
Integrating catheter-based probes or endoscopic approaches into the PA imaging platform could address current limitations and enhance the translational potential of this technology for bladder cancer diagnosis and monitoring therapeutic responses.
